DOX
Amdocs Limited
DOX trails on the overall score without a compensating advantage in the available component scores.
NVDA
NVIDIA Corporation
NVDA has the edge over DOX overall, supported by stronger modeled upside and stronger fundamentals.
DOX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Healthy |
DOX's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
DOX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 8.1x | $44.11 | — |
| Current | 11x | $44.11 | — |
| Cheap | 14x | $60.81 | +38% |
| Fair | 18x | $76.51 | +73% |
| Expensive | 20x | $85.23 | +93% |
Historical ranges are pointers, not guarantees.
DOX's PE is in its cheap range at 11x. On analysts' estimates for next year's earnings, today's price would be 8.1x.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over DOX in the historical PE scenario, which offers more potential upside but is not a forecast.
DOX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong decline | |
| Decline | |
| Weakening | |
| Limited | |
| Low |
Analysts expect DOX's earnings and revenue to decline, with profitability weakening. However, they disagree widely on these estimates.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
NVDA has the edge over DOX on the outlook, with more favorable earnings and revenue expectations.
DOX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.47 | +30% |
| Q2 2026 | $4.20 | -14% |
| Q1 2026 | $5.00 | +5.9% |
| Q4 2025 | $5.17 | +21% |
| Q3 2025 | $5.05 | +20% |
| Q2 2025 | $4.90 | +13% |
| Q1 2025 | $4.72 | +6.1% |
| Q4 2024 | $4.28 | -8.4% |
| Q3 2024 | $4.21 | -6% |
DOX earned $4.20 per share over the past year, down 14% from the year before.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over DOX on earnings, with more consistent year-over-year improvement.
DOX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $1.2B | +2.7% |
| Q1 2026 | $1.2B | +3.9% |
| Q4 2025 | $1.2B | +4.1% |
| Q3 2025 | $1.2B | -9% |
| Q2 2025 | $1.1B | -8.4% |
| Q1 2025 | $1.1B | -9.4% |
| Q4 2024 | $1.1B | -11% |
| Q3 2024 | $1.3B | +1.7% |
DOX's revenue grew through 2021 and has held roughly level since: $1.2B last quarter, up 2.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 18% | +0.3 points |
| Q1 2026 | 16% | -1.1 points |
| Q4 2025 | 18% | 0 points |
| Q3 2025 | 18% | +9 points |
| Q2 2025 | 18% | +3.6 points |
| Q1 2025 | 18% | +5 points |
| Q4 2024 | 18% | +3.1 points |
| Q3 2024 | 8.9% | -2.3 points |
DOX's operating margin was 18% last quarter, about level with the same quarter a year ago, near the top of its range since 2019.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over DOX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over DOX on profitability, with a higher operating margin.
DOX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $171.9M | -19% |
| Q1 2026 | $80.3M | -49% |
| Q4 2025 | $187.9M | +140% |
| Q3 2025 | $198.6M | +3.4% |
| Q2 2025 | $211.8M | +21% |
| Q1 2025 | $156.5M | +38% |
| Q4 2024 | $78.2M | -44% |
| Q3 2024 | $192.1M | -22% |
DOX's free cash flow has been positive every quarter for seven years: $639M over the past year, about the same as the year before.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over DOX on cash flow, with more consistent year-over-year improvement.
DOX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.7% | -1.8M shares |
| 1 year | -4.9% | -5.5M shares |
| 3 years | -12% | -14.7M shares |
| 5 years | -17% | -22.4M shares |
| Available history | -22% | -30.5M shares |
DOX has the edge over NVDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $142.6M |
| Q1 2026 | $138.3M |
| Q4 2025 | $146.2M |
| Q3 2025 | $136.4M |
| Q2 2025 | $135.2M |
| Q1 2025 | $135.2M |
| Q4 2024 | $144.5M |
| Q3 2024 | $119.8M |
DOX spent $563M buying back its own shares over the past year, up 5.4% from the year before.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has 24.3B diluted shares, down 1% from a year ago, with $55.3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
DOX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.0x | Healthy |
| Q1 2026 | 0.9x | Very low |
| Q4 2025 | 0.7x | Very low |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 0.7x | Very low |
| Q1 2025 | 0.7x | Very low |
| Q4 2024 | 0.7x | Very low |
| Q3 2024 | 0.6x | Very low |
DOX's net debt is about a year of its operating earnings (EBITDA), up from less than a year a year ago.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA has the edge over DOX on leverage, with a lower net debt burden relative to earnings.
DOX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.4 | Neutral |
| Stochastic | 36.7 | Neutral |
DOX's weekly RSI is 30 (neutral) and its Stochastic is 37 (neutral).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
DOX PE vs Technology Sector
| Metric | DOX | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 28x | 62% below |
| PE % | 2 | 35 | 33 pts below |
DOX has the edge over NVDA on valuation relative to its sector.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
DOX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $55.8 | 21% below |
| 20 week MA | $56.7 | 22% below |
| 50 week MA | $64.2 | 31% below |
| 100 week MA | $75.3 | 41% below |
| 200 week MA | $81.7 | 46% below |
DOX is in a downtrend: it's below all five of its weekly moving averages, and 46% below its 200-week average.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has the edge over DOX on trend strength, trading above more of its moving averages.
DOX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $72.6 | $69.7 | -4.1% |
| 2021 | $69.7 | $74.3 | +6.7% |
| 2022 | $74.3 | $89.4 | +20% |
| 2023 | $89.4 | $87.9 | -1.6% |
| 2024 | $87.9 | $85.8 | -2.4% |
| 2025 | $85.8 | $81.7 | -4.7% |
| 2026 YTD | $81.7 | $44.1 | -46% |
DOX has finished three years in a row lower, and it's down 46% so far in 2026.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA has the edge over DOX on returns for 2026, with the stronger performance.